` GLMD (Galmed Pharmaceuticals Ltd) vs S&P 500 Comparison - Alpha Spread

GLMD
vs
S&P 500

Over the past 12 months, GLMD has underperformed S&P 500, delivering a return of -78% compared to the S&P 500's +14% growth.

Stocks Performance
GLMD vs S&P 500

Loading
GLMD
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
GLMD vs S&P 500

Loading
GLMD
S&P 500
Difference
www.alphaspread.com

Performance By Year
GLMD vs S&P 500

Loading
GLMD
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Galmed Pharmaceuticals Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Galmed Pharmaceuticals Ltd
Glance View

Market Cap
3.3m USD
Industry
Biotechnology

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

GLMD Intrinsic Value
3.767 USD
Undervaluation 84%
Intrinsic Value
Price
Back to Top